Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
The January 2012 issue of Oncology contains an open access, full-text article on the future sequencing of the recently approved and potentially new drugs that are or should soon be available for the treatment of advanced prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, drugs, new, sequencing | 1 Comment »
Many patients feel strongly about the need for management of their clinical care by one or more doctors who truly specialize in the management of prostate cancer — and as the available knowledge about appropriate management of the different types and stages of prostate cancer has grown, this is an entirely understandable point of view.
Filed under: Living with Prostate Cancer, Management | Tagged: advanced, medical oncologist, subspecialist | 1 Comment »
Many prostate cancer patients and advocates will want to read yesterday’s article by New York Times correspondent Andrew Pollack entitled, “New drugs fight prostate cancer, but at high cost.” The article offers a commentary on recent advances in the treatment of advanced prostate cancer — and the economic consequences.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: advanced, cost, drugs | Comments Off
The Prostate Cancer Clinical Trials Consortium (PCCTC) has initiated a Phase II clinical trial of an oral taxane known as tesetaxel in the treatment of metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Drugs in development, Management, Uncategorized | Tagged: advanced, mCRPC, tesetaxel | Leave a Comment »
According to a Reuters report based on a recent media release from GTx, the investigational agent GTx-758 is able to induce temporary medical castration in healthy volunteers, making this agent yet another possible candidate for the hormonal management of progressive prostate cancer.
Filed under: Drugs in development | Tagged: advanced, castration, GTx-758 | Leave a Comment »
On his Advanced Prostate Cancer blog site, Joel Nowak has just published a series of five brief articles on the opportunities offered by some older agents that are available for use as second-line therapies in the management of patients who have a rising PSA after treatment with standard forms of androgen deprivation therapy (ADT).
Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: advanced, castration-resistant, CRPC, estradiol, GM-CSF, ketoconazole, octreotide | 3 Comments »
In June 2009 we reported on data suggesting that the monocolonal antibody ipilimumab appeared to be capable of “downstaging” more advanced forms of prostate cancer such that the patients became re-eligible for localized therapy with curative intent. It’s time for an update based on data presented at the Genitourinary Cancers Symposium last Friday and Saturday.
Filed under: Drugs in development, Management, Treatment | Tagged: advanced, down-stageing, ipilimumab, locallly advanced | Leave a Comment »
Please note that this report has been modified from the original now that we have been able to obtain an actual copy of the full paper. According to a new report by Grace Lu-Yao and colleagues, published yesterday in the Journal of the National Cancer Institute, “Men with prostate cancer are being diagnosed at a [...]
Filed under: Diagnosis, Management, Risk | Tagged: advanced, risk | 1 Comment »
Today’s prostate cancer news reports address articles on: The role of MRI in prostate cancer diagnosis The accuracy of different types of MR imaging Removal of the seminal vesicles in surgical treatment of low-risk disease Current treatment strategies for advanced prostate cancer
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: advanced, low risk, magnetic resonance imaging, MRI, seminal vesicles, surgery | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site